DC Field | Value | Language |
---|---|---|
dc.contributor.author | Seulki Park | - |
dc.contributor.author | D Kim | - |
dc.contributor.author | W Lee | - |
dc.contributor.author | Jin Hwa Cho | - |
dc.contributor.author | Sungyoung Kim | - |
dc.contributor.author | Ga Seul Lee | - |
dc.contributor.author | Jeong Hee Moon | - |
dc.contributor.author | Jung Ae Kim | - |
dc.contributor.author | J D Ha | - |
dc.contributor.author | Jeong Hoon Kim | - |
dc.contributor.author | H J Kim | - |
dc.date.accessioned | 2022-11-21T16:32:50Z | - |
dc.date.available | 2022-11-21T16:32:50Z | - |
dc.date.issued | 2023 | - |
dc.identifier.issn | 0223-5234 | - |
dc.identifier.uri | https://oak.kribb.re.kr/handle/201005/30623 | - |
dc.description.abstract | Inhibitors of apoptosis proteins (IAPs), defined by the presence of baculovirus IAP repeat (BIR) protein domain, are critical regulators of cell survival and cell death processes. Cellular IAP 1/2 (cIAP1/2) and X-linked IAPs (XIAPs) regulate the innate immune signaling pathway through their E3 ubiquitin ligase activity. Peptidomimetics or small-molecule IAP antagonists have been developed to treat various diseases, such as cancer, infection, and inflammation. In this study, we synthesized and characterized IAP?cereblon (CRBN) heterodimerizing proteolysis-targeting chimera (PROTAC), which induces the degradation of cIAP1/2 and XIAP but not CRBN. We demonstrated that this PROTAC inhibits tumor necrosis factor alpha (TNFα)-induced innate immune response and cancer cell migration and invasion, leading to apoptotic cell death. Our study is the first to demonstrate that both cIAPs and XIAP are degradable when applied to the PROTAC strategy. | - |
dc.publisher | Elsevier | - |
dc.title | Discovery of pan-IAP degraders via a CRBN recruiting mechanism | - |
dc.title.alternative | Discovery of pan-IAP degraders via a CRBN recruiting mechanism | - |
dc.type | Article | - |
dc.citation.title | European Journal of Medicinal Chemistry | - |
dc.citation.number | 2 | - |
dc.citation.endPage | 114910 | - |
dc.citation.startPage | 114910 | - |
dc.citation.volume | 245 | - |
dc.contributor.affiliatedAuthor | Seulki Park | - |
dc.contributor.affiliatedAuthor | Jin Hwa Cho | - |
dc.contributor.affiliatedAuthor | Sungyoung Kim | - |
dc.contributor.affiliatedAuthor | Ga Seul Lee | - |
dc.contributor.affiliatedAuthor | Jeong Hee Moon | - |
dc.contributor.affiliatedAuthor | Jung Ae Kim | - |
dc.contributor.affiliatedAuthor | Jeong Hoon Kim | - |
dc.contributor.alternativeName | 박슬기 | - |
dc.contributor.alternativeName | 김다영 | - |
dc.contributor.alternativeName | 이우리 | - |
dc.contributor.alternativeName | 조진화 | - |
dc.contributor.alternativeName | 김성영 | - |
dc.contributor.alternativeName | 이가슬 | - |
dc.contributor.alternativeName | 문정희 | - |
dc.contributor.alternativeName | 김정애 | - |
dc.contributor.alternativeName | 하재두 | - |
dc.contributor.alternativeName | 김정훈 | - |
dc.contributor.alternativeName | 김현진 | - |
dc.identifier.bibliographicCitation | European Journal of Medicinal Chemistry, vol. 245, no. 2, pp. 114910-114910 | - |
dc.identifier.doi | 10.1016/j.ejmech.2022.114910 | - |
dc.subject.keyword | Inhibitor of apoptosis (IAP) | - |
dc.subject.keyword | CRBN | - |
dc.subject.keyword | PROTAC | - |
dc.subject.keyword | Caspase | - |
dc.subject.keyword | EMT | - |
dc.subject.keyword | TD-1092 | - |
dc.subject.local | Inhibitor of apoptosis (IAP) | - |
dc.subject.local | CRBN | - |
dc.subject.local | crbn | - |
dc.subject.local | PROTAC | - |
dc.subject.local | protac | - |
dc.subject.local | Caspase | - |
dc.subject.local | Caspases | - |
dc.subject.local | caspase | - |
dc.subject.local | EMT | - |
dc.subject.local | TD-1092 | - |
dc.description.journalClass | Y | - |
There are no files associated with this item.
Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.